COMPANY PROFILE

Convergent Therapeutics

Explore full profile

Convergent Therapeutics is developing next-generation radiopharmaceutical therapies to treat prostate cancer and beyond

Cambridge, United StatesFounded 2021Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2024

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Convergent Therapeutics

Convergent Therapeutics, Inc. is a biotechnology company dedicated to developing next-generation targeted radiotherapies aimed at improving outcomes for cancer patients. The company operates in the healthcare and biotechnology markets, focusing on innovative cancer treatments. Convergent Therapeutics serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around research and development (R&D) of advanced radiotherapy solutions, which are then commercialized through partnerships, licensing agreements, and direct sales. Revenue is generated primarily through these partnerships and the commercialization of their proprietary therapies.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: Cambridge, United States
Employees: 38
Open positions: 1
Dealroom signal: 91.8/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning Convergent Therapeutics.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Sep 2024	$40M	$450M	Novo Holdings	↗
SERIES AOther financing	May 2023	$90M	$360M	RA Capital Management · Invus · OrbiMed	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Convergent Therapeutics website traffic

Latest recorded traffic for Convergent Therapeutics is 1.8K monthly website visits, down 28% over the last three months. Convergent Therapeutics's team grew 35.7% over the past year.

Latest monthly visits1.8K 3-month web change-28% 1-year team growth+35.7%

Monthly website visitsDec 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PAPanacea-mlExplainable-AI Platform to Streamline Clinical Trial Design	Ra'anana, Israel	Operational	2	$1M	$3.7M
DCDCGenCreating better life for patients with personalized	Seoul, South Korea	Operational
OTOlatec TherapeuticsLeaders in the Clinical Development of Inflammasome Therapeutics	New York City, United States	Operational
CACannaSoul AnalyticsInnovative therapeutics from natural compounds, bridging botanical medicine and the pharmaceutical industry	Caesarea, Israel	Operational
STSeed TherapeuticsPioneering the science of improving human health	New York City, United States	Operational
MTMarch TherapeuticsBuilding scalable therapeutics platform with mitochondrial genome editors	Cambridge, United States	Operational
CTCERES BRAIN TherapeuticsNeuron-rescuing therapies for neurological bioenergetic diseases	Paris, France	Operational
LILinusBioPatient-centric precision exposome medicine, uncovering biomarkers and targets for diseases with historically limited molecular endpoints, spanning CNS, gastroenterology, renal disease, and oncology	North Brunswick Township, United States	Operational